SCHEMBL17309999

SCHEMBL17309999

COc1cnc(-c2cnc(N)c(OC(C)c3c(Cl)ccc(F)c3Cl)c2)cc1N1CCNCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 14/20 1.00
JAK2 O60674 2/20 0.70
INSR P06213 1/20 0.62
NPM1 P06748 1/20 0.62
MET P08581 5/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15933024 1.00 ALK (1.00) ALKJAK2INSRNPM1MET
SCHEMBL17310217 0.86 ALK (1.00) ALKJAK2INSRNPM1MET
SCHEMBL15933022 0.86 ALK (1.00) ALKJAK2INSRNPM1MET
SCHEMBL17310229 0.85 ALK (1.00) ALKJAK2MET
SCHEMBL15933023 0.85 ALK (1.00) ALKJAK2MET
SCHEMBL17310091 0.85 ALK (0.74) ALKJAK2MET
SCHEMBL17310092 0.85 ALK (0.74) ALKJAK2MET
SCHEMBL15933026 0.84 ALK (1.00) ALKJAK2INSRNPM1MET
SCHEMBL15933011 0.84 ALK (1.00) ALKJAK2INSRNPM1MET
SCHEMBL17310169 0.84 ALK (1.00) ALKJAK2INSRNPM1MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2952510-B1 SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2018-12-26 EP disclosed
US-9708295-B2 Substituted 2-aminopyridine protein kinase inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2017-07-18 US disclosed
US-20160002205-A1 SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) 2016-01-07 US disclosed
EP-2952510-A1 SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) 2015-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002205-A1 SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR PACSIN2, MAPKAPK2, PRKCA ALK 853/4885JAK2 312/4885INSR 2142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.